• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Sesen Bio reach­es deal with in­vestor group, paving way for Caris­ma merg­er

3 years ago
Financing
Deals

A Texas-based biotech be­comes the lat­est to en­ter the SPAC scene

3 years ago
Financing
Deals

With a year full of read­outs ahead, Disc Med­i­cine se­cures cash from Bain Cap­i­tal

3 years ago
R&D

Up­dat­ed: FDA adds warn­ing of 'larg­er ar­eas of bleed­ing' in brain to Bio­gen's Aduhelm la­bel

3 years ago
FDA+

FDA hands down RTF let­ter to rare dis­ease biotech's lead can­di­date

3 years ago
R&D
FDA+

GSK re­vis­es Covid deal with Vir, pulls out of next-gen work

3 years ago
Deals
R&D

Har­vard pro­fes­sor takes on the man­tle of Gavi CEO

3 years ago
People

PRO­TACs to RIP­TACs: Arv­inas founder snags $76M for next bet, Hal­da Ther­a­peu­tics

3 years ago
Financing
Startups

Re­play part­ners with MD An­der­son’s Katy Rez­vani, heads to clin­ic with new TCR NK cell com­pa­ny

3 years ago
Financing
Startups

John Reed lands in the top R&D post at J&J in his lat­est Big Phar­ma de­but

3 years ago
People
Bioregnum

Should Nar­can spray be sold over the counter? FDA pos­es po­ten­tial pack­ag­ing changes

3 years ago
Pharma
FDA+

US gov­ern­ment, Pfiz­er and oth­ers side with Sanofi and Re­gen­eron in Supreme Court patent case

3 years ago
Pharma
Law

Sun Phar­ma is­sues re­call for more than 34,000 bot­tles of blood pres­sure med­ica­tion

3 years ago
Pharma
FDA+

Gilead­'s Kite clues pa­tients in with con­ver­sa­tion­al CAR-T cell ther­a­py cam­paign

3 years ago
Pharma
Marketing

FDA re­jects Bio­con and Vi­a­tris' Avastin biosim­i­lar af­ter in­spec­tion ques­tion marks

3 years ago
Pharma
FDA+

Op­er­a­tion Warp Speed for rare dis­eases: CBER leader says pi­lot is com­ing soon

3 years ago
FDA+

In­cyte says un­der-the-radar JAK in­hibitor clears a high bar for skin dis­or­der

3 years ago
R&D

Vivek Ra­maswamy plan­ning a run for US pres­i­dent — re­port

3 years ago
People

Giv­ing first glimpse of da­ta, Scan­cell looks for Covid-19 vac­cine part­ner

3 years ago
R&D
Coronavirus

Third time’s the charm: Cere­vance’s Se­ries B ex­pands again

3 years ago
Financing
Startups

Fre­quen­cy Ther­a­peu­tics re­ports tri­al fail and lays off over half of staff — stock cap­sizes

3 years ago
R&D

G1 Ther­a­peu­tics aban­dons PhI­II col­orec­tal can­cer tri­al af­ter dis­ap­point­ing over­all re­sponse rates

3 years ago
R&D

Up­dat­ed: Sor­ren­to files for Chap­ter 11 af­ter los­ing ar­bi­tra­tion to Patrick Soon-Sh­iong biotech

3 years ago
Pharma

Sanofi’s R&D chief John Reed makes sur­prise ex­it

3 years ago
People
First page Previous page 376377378379380381382 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times